In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain
about
The potential for emerging therapeutic options for Clostridium difficile infectionTigecycline: first of a new class of antimicrobial agentsPharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsTelithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrationsEffects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.Acinetobacter baumannii: emergence of a successful pathogenIn vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistanceOritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.Tigecycline: a new glycylcycline for treatment of serious infections.Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.Tigecycline: a novel glycylcycline antibiotic.In vitro activities of tigecycline against the Bacteroides fragilis group.In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in ItalyTreatment options for multidrug-resistant bacteria.Targeting cancer cell mitochondria as a therapeutic approach.Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem.The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells.A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.Evaluation of Tigecycline Activity Against Methicillin-Resistante Staphylococcus aureus Isolated from Biological Samples.In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae.Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs.In vitro activity of tigecycline against Bacteroides species.Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicenter study.
P2860
Q28082059-901A8957-3BA0-4308-9F51-8F789B92839AQ28253736-E8A3D26D-068D-471C-8DB5-CC06BDB6463FQ29398341-BFE207A5-BD8F-49F1-933B-D94C8BDE3201Q30806051-E9DFBD97-9F3F-4A84-B50D-FC2BCA65CB6DQ33722056-629D4662-900D-41BD-B913-946049D0652CQ33722140-DD070C99-E11F-45E9-B422-07257F934405Q34795807-1C56AD9D-5854-4FEE-8BF2-2850D48D47C5Q35007097-016B1D38-D213-488C-AE44-1B6A623A0AEAQ35637071-EE14007F-E661-4ABE-9C86-594640A648A1Q35758970-8E86BFA0-6CBC-4CB6-9C8D-B0303A2FCE6FQ36218312-94200822-A734-4D82-99CE-84143E9CDA65Q36312068-E8470E58-4990-4EE7-BF77-6F7C1BA08E35Q36322117-AE2D7BD7-D5A2-4184-AF44-8270156B59BBQ36379330-625A5C2A-6EFB-4BA0-B94C-F353BD5B65DBQ36490533-82CDEC20-9D5A-44EF-9A6F-945068D5977DQ36509591-8423C344-4BBD-47AA-8E01-68B7772B9A32Q36607401-CCDAEDAB-94E6-42FC-BFFF-97D6E11ADBF9Q36655323-EA4CF8B7-D845-4D21-A05E-9408AD56CC52Q39730764-81571F59-1031-4827-A684-415D2BF8A6C3Q39792528-DDA8EA97-446F-4C5F-A30F-EF270153F896Q40290852-87771128-2F2A-4849-8077-9CDB7D0E1D80Q40647464-DE2EFFAA-2326-43CD-ABF9-6CBAC60A92DBQ41111507-95772047-4BB2-4618-95B5-E67621404838Q42112359-1A6732C2-EC06-47F9-956A-E2105BE0AF6DQ42781919-0EFD87FE-2A8E-4D87-900E-CE0BF591EB06Q43120139-3A49E1C0-6176-46B1-A893-699D8E9F2FE6Q45945783-7F111EBA-8E82-4E51-A668-307057E096F7Q46542090-C77E7081-C775-48D5-9A9B-EE25CE929C1AQ46852074-912A159A-91BA-437C-8220-D92AE5C49C5F
P2860
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@ast
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@en
type
label
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@ast
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@en
prefLabel
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@ast
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@en
P2093
P2860
P1476
In vitro activities of tigecyc ...... ted clinical bacteria in Spain
@en
P2093
Blas Ali Sánchez
Carmen Betriu
Iciar Rodríguez-Avial
Juan Alvarez
Juan J Picazo
María Gómez
Spanish Group of Tigecycline
P2860
P304
P356
10.1128/AAC.46.3.892-895.2002
P407
P577
2002-03-01T00:00:00Z